Article

A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosis

2020-08-25

Abstract excerpt

Emerging multidrug-resistant tuberculosis is a major global health challenge. The World Health Organization currently recommends treatment durations of 9–18 months or more for patients with multidrug-resistant tuberculosis. We identified and validated a host-RNA signature to serve as a biomarker for individualized therapy durations for patients with multidrug-resistant tuberculosis. Adult patients with pulmonary t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f550decb-c2a6-5838-b69f-44a14b94223a
DOI: 10.1101/2020.08.21.20177238

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A 22-gene transcriptomic model indicating individual therapy durations in multidrug-resistant tuberculosisDOI 10.1101/2020.08.21.20177238Read

Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic modelSemantic proximity Read

A new blood-based RNA signature (R9), for monitoring effectiveness of tuberculosis treatment in a South Indian longitudinal cohortSemantic proximity Read

Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in BrazilSemantic proximity Read

RISK6 as a Translational Host Transcriptomic Signature for Tuberculosis Diagnosis, Treatment Monitoring, and Risk StratificationSemantic proximity Read

Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatmentSemantic proximity Read

Whole blood vs serum-derived exosomes for host and pathogen-specific tuberculosis biomarker identification: RNA-seq based machine learning approachSemantic proximity Read

Common gene signature model discovery and systematic validation for TB prognosis and response to treatmentSemantic proximity Read

Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatmentSemantic proximity Read

Circulating Cell-Free RNA in Blood as a Host Response Biomarker for the Detection of TuberculosisSemantic proximity Read

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trialSemantic proximity Read

RISK6, a universal 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseSemantic proximity Read

Gene expression signatures identify biologically and clinically distinct tuberculosis endotypesSemantic proximity Read